Literature DB >> 21755509

Increased serum interleukin-17 levels in patients with myasthenia gravis.

Jose C Roche1, Jose L Capablo, Luis Larrad, Javier Gervas-Arruga, Jose R Ara, Alejandro Sánchez, Raquel Alarcia.   

Abstract

It has been suggested that interleukin-17 (IL-17) plays a crucial role in the development of several autoimmune diseases. However, there are no data about the relationship between myasthenia gravis and IL-17. The aim of this study was to measure the concentration of IL-17 and determine whether levels depend on the severity of MG. Serum IL-17 concentrations were measured in 25 patients. IL-17 concentrations were higher in generalized MG compared with controls and correlated with anti-acetylcholinesterase receptor antibody titers.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21755509     DOI： 10.1002/mus.22070

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


  27 in total

1.  Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response.

Authors:  Jiao Wang; Shuangshuang Zheng; Ning Xin; Changxin Dou; Linlin Fu; Xiuying Zhang; Jing Chen; Yanyan Zhang; Deqin Geng; Chenghua Xiao; Guiyun Cui; Xia Shen; Yang Lu; Jinhua Wang; Ruiguo Dong; Yuehua Qiao; Yong Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2013-09-17       Impact factor: 4.147

2.  Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Authors:  Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi
Journal:  Exp Neurol       Date:  2018-11-22       Impact factor: 5.330

3.  Decreased microRNA miR-181c expression in peripheral blood mononuclear cells correlates with elevated serum levels of IL-7 and IL-17 in patients with myasthenia gravis.

Authors:  Yong Zhang; Mingfeng Guo; Ning Xin; Zhen Shao; Xiuying Zhang; Yanyan Zhang; Jing Chen; Shuangshuang Zheng; Linlin Fu; YuZhong Wang; Dongmei Zhou; Hao Chen; Yan Huang; Ruiguo Dong; Chenghua Xiao; Yonghai Liu; Deqin Geng
Journal:  Clin Exp Med       Date:  2015-05-12       Impact factor: 3.984

Review 4.  Future perspectives in target-specific immunotherapies of myasthenia gravis.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

5.  Inhibition of the transcription factor ROR-γ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis.

Authors:  John S Yi; Melissa A Russo; Shruti Raja; Janice M Massey; Vern C Juel; Jay Shin; Lisa D Hobson-Webb; Karissa Gable; Jeffrey T Guptill
Journal:  Exp Neurol       Date:  2019-12-12       Impact factor: 5.330

6.  TIPE2 Play a Negative Role in TLR4-Mediated Autoimmune T Helper 17 Cell Responses in Patients with Myasthenia Gravis.

Authors:  Yong Zhang; Zhen Shao; Xiuying Zhang; Xiao Jia; Yan Xia; Yanyan Zhang; Ning Xin; Mingfeng Guo; Jing Chen; ShuangShuang Zheng; YuZhong Wang; Linlin Fu; Ruiguo Dong; Chenghua Xiao; Deqin Geng; Yonghai Liu
Journal:  J Neuroimmune Pharmacol       Date:  2015-10-24       Impact factor: 4.147

Review 7.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

8.  Serum cytokine and chemokine profiles in patients with myasthenia gravis.

Authors:  A Uzawa; N Kawaguchi; K Himuro; T Kanai; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

9.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

Review 10.  Immunotherapy in myasthenia gravis in the era of biologics.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.